Moody Aldrich Partners LLC Purchases New Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Moody Aldrich Partners LLC acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 74,372 shares of the company's stock, valued at approximately $1,349,000. Moody Aldrich Partners LLC owned about 0.23% of Dianthus Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TCG Crossover Management LLC bought a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $32,735,000. Braidwell LP lifted its position in shares of Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after purchasing an additional 712,902 shares during the period. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after purchasing an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP increased its position in shares of Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after buying an additional 363,500 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new position in Dianthus Therapeutics during the fourth quarter worth $3,924,000. Institutional investors own 47.53% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on DNTH shares. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. William Blair assumed coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Robert W. Baird reduced their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Finally, Guggenheim restated a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $53.00.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded down $0.60 during mid-day trading on Monday, reaching $18.25. 215,078 shares of the company's stock traded hands, compared to its average volume of 264,657. The stock has a market cap of $586.92 million, a P/E ratio of -6.34 and a beta of 1.38. The business has a 50-day simple moving average of $18.85 and a 200 day simple moving average of $20.42. Dianthus Therapeutics, Inc. has a 1-year low of $13.37 and a 1-year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. The firm had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,544.23% and a negative return on equity of 29.26%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.